Dawson James Reiterates Buy Rating on Sorrento Therapeutics (SRNE) on FDA Clearance for Phase 2 of Abivertinib in COVID-19
Go back to Dawson James Reiterates Buy Rating on Sorrento Therapeutics (SRNE) on FDA Clearance for Phase 2 of Abivertinib in COVID-19| SORRENTO THERAPEUT (AMEX: SRNE) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $10.26 | |||
| Open | $0.00 | 52 Week Low | $4.25 | |||
| Day High | $0.00 | P/E | 0.00 | |||
| Day Low | $0.00 | EPS | $-0.50 | |||
| Volume | 9,930 | |||||
